|
|
|
|
New Market Research Report
Rheumatoid Arthritis
Therapeutics - Pipeline
Assessment and Market
Forecasts to 2018 |
|
|
|
|
Pharmaceuticals |
 |
|
|
|
|
|
| Rheumatoid Arthritis Therapeutics Market is Forecast to Show Moderate Growth Until 2018 |
GlobalData’s
analysis
suggests
that the
global
rheumatoid
arthritis
therapeutics
market
was
worth
$10.3
billion
in 2010
and
forecast
to grow
at a
CAGR of
3.8% to
reach
$13.8
billion
by 2018.
The high
growth
rate
during
2005-2010
is
primarily
attributed
to the
launch
of
biologics
such as
Enbrel
(etanercept),
Remicade |
|
 |
(infliximab),
Humira
(adalimumab) and
Rituxan
(rituximab). The
growth was
further fuelled
by the launch of
safer and more
efficacious
biologics.
During
2010-2018, the
rheumatoid
arthritis
therapeutics
market is
expected to see
moderate growth
due to patent
expiries of
major biologics
and the
subsequent
launch of
biosimilars in
the market.
Rheumatoid
Arthritis
Therapeutics
Market has
Moderate Unmet
Need
The current
therapeutics
landscape for
rheumatoid
arthritis has
products that
are efficacious
but not
curative. The
efficacy of
current product
offerings in the
rheumatoid
arthritis
therapeutics
market is
significant in
terms of
addressing
disease symptoms
and improving
the lifestyle of
patients. Since
rheumatoid
arthritis is a
heterogeneous
disease,
patients’
response to the
treatment is
different; some
patients respond
to DMARD
monotherapy
whereas others
respond to
combination
therapies. As a
result it
remains a major
challenge to
determine which
combination is
right for each
patient.
GlobalData's
report
"Rheumatoid
Arthritis
Therapeutics -
Pipeline
Assessment and
Market Forecasts
to 2018"
identifies key
trends shaping
and driving the
global
rheumatoid
arthritis
therapeutics
market. The
report provides
insights on the
prevalent
competitive
landscape and
emerging players
expected to
significantly
alter the market
positioning of
the current
market leaders.
Most
importantly, the
report provides
valuable
insights on the
pipeline
products within
the global
rheumatoid
arthritis
therapeutics
sector. This
report is built
using data and
information
sourced from
proprietary
databases,
primary and
secondary
research and
in-house
analysis by
GlobalData’s
team of industry
experts.
This
report will
provide you
with...
|
• |
Pipeline
analysis
data
providing
a split
across
the
different
phases,
mechanisms
of
action
being
developed
and
emerging
trends
by seven
key
markets |
|
• |
Annualized
market
revenues
data for
seven
key
markets:
the US,
France,
Germany,
Italy,
Spain,
UK and
Japan.
Data
from
2006 to
2010,
forecast
to 2018 |
|
• |
Analysis
of the
current
and
future
competition
in the
seven
key
countries
|
|
• |
Insightful
review
of the
key
industry
drivers,
restraints
and
challenges.
Each
trend is
independently
researched
to
provide
a
qualitative
analysis
of its
implications
|
|
• |
Key
topics
covered
include
strategic
competitor
assessment,
market
characterization,
unmet
needs
and
implications
|
|
• |
Analysis
of
key
recent
licensing
and
partnership
agreements
in the
Rheumatoid
Arthritis
Therapeutics
market. |
|
|
|
|
|
Report
Information |
|
|
Order Rheumatoid
Arthritis
Therapeutics
-
Pipeline
Assessment
and
Market
Forecasts
to 2018
today!
•
Price:
$3,500
(single
user
license)
•
Published:
October
2011
•
Publisher:
GlobalData |
Report Contains |
|
| Pages: 131 |
| Data Tables: 60 |
| Figure Count: 37 |
|
| Key Countries Covered |
|
| The US, France, Germany, Italy, Spain, UK and Japan |
|
|
 |
|
|
Other
Best-Selling
Reports |
|
|
Neuropathic
Pain
Therapeutics
-
Pipeline
Assessment
and
Market
Forecasts
to 2018
Published
September
2011
Find out
more...
Idiopathic
Pulmonary
Fibrosis
(IPF)
Therapeutics
-
Pipeline
Assessment
and
Market
Forecasts
to 2018
Published
September
2011
Find out
more...
|
|
|
|
|
|
|
|
|
© GlobalData |
|
John Carpenter House, John Carpenter Street,
London, EC4Y 0AN, UK |
|
|
To top
|
|
